294 related articles for article (PubMed ID: 21523797)
1. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797
[TBL] [Abstract][Full Text] [Related]
2. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.
Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Holtan SG; Pardanani A; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
Leukemia; 2010 Jul; 24(7):1283-9. PubMed ID: 20485371
[TBL] [Abstract][Full Text] [Related]
3. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
4. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
5. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia with isolated del(5q) is associated with IDH1/IDH2 mutations and better prognosis when compared to acute myeloid leukemia with complex karyotype including del(5q).
Rea B; Aggarwal N; Yatsenko SA; Bailey N; Liu YC
Mod Pathol; 2020 Apr; 33(4):566-575. PubMed ID: 31685963
[TBL] [Abstract][Full Text] [Related]
8. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
[TBL] [Abstract][Full Text] [Related]
9. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
[TBL] [Abstract][Full Text] [Related]
10. Myeloid neoplasm with isolated del(5q) and the MPLW515L mutation fulfills the WHO diagnostic criteria for ET.
Kirito K
Int J Hematol; 2020 Aug; 112(2):238-242. PubMed ID: 32246278
[TBL] [Abstract][Full Text] [Related]
11. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
13. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
14. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
15. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
Germing U; Lauseker M; Hildebrandt B; Symeonidis A; Cermak J; Fenaux P; Kelaidi C; Pfeilstöcker M; Nösslinger T; Sekeres M; Maciejewski J; Haase D; Schanz J; Seymour J; Kenealy M; Weide R; Lübbert M; Platzbecker U; Valent P; Götze K; Stauder R; Blum S; Kreuzer KA; Schlenk R; Ganser A; Hofmann WK; Aul C; Krieger O; Kündgen A; Haas R; Hasford J; Giagounidis A
Leukemia; 2012 Jun; 26(6):1286-92. PubMed ID: 22289990
[TBL] [Abstract][Full Text] [Related]
16. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
18. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.
Nguyen-Khac F; Lesty C; Eclache V; Couronné L; Kosmider O; Andrieux J; Collonge-Rame MA; Penther D; Lafage M; Bilhou-Nabera C; Chapiro E; Mozziconacci MJ; Mugneret F; Gachard N; Nadal N; Lippert E; Struski S; Dastugue N; Cabrol C; Bernard OA;
Genes Chromosomes Cancer; 2010 Oct; 49(10):919-27. PubMed ID: 20629097
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F mutation is associated with 5q- syndrome in Chinese.
Wong KF; Wong WS; Siu LL; Lau TC; Chan NP
Leuk Lymphoma; 2009 Aug; 50(8):1333-5. PubMed ID: 19562618
[TBL] [Abstract][Full Text] [Related]
20. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
